Approval of Q 1 financial results FY 2026-27 in alia, considered other matters.

FISCHER MEDICAL VENTURES LIMITED (Formerly known as Fischer Chemic Limited) Registered Office Address: Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032 CIN: L86900AP1993PLC118162 Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548 August 14, 2026 BSE Limited National Stock Exchange of India Ltd. Corporate Relationship Department Exchange Plaza, 5tll floor 25th Floor, P J Towers Plot No. C/ 1, G Block, Dalal Street, Fort, Bandra-Kurla Complex Bandra (E), Mumbai – 400 001. Mumbai - 400 051. BSE Scrip Code: 524743 NSE Symbol: FISCHER Dear Sir/ Madam, Sub: Outcome of Board Meeting held on 14th August, 2026 Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (14/08/2026): 1. Financial Results Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Period ended 30/06/2026 in the format specified under the SEBI (Listing Obligations and Disclosure Requirements) Regulations ,2015 ('SEBI Listing Regulations"), together with a copy of the Limited Review Reports of M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai for your records. The aforesaid Unaudited Financial Results are also uploaded on the Company's website www.fischermv.com. An extract of the aforesaid Unaudited Financial Results, in the manner prescribed under the SEBI Listing Regulations, is annexed herewith in Annexure-1 and the same will be published in English and Telugu newspapers within the time stipulated. 2. Resignation of Independent Directors Noted the Resignation of the Mr. Roberto M Pagdanganan, Independent Director (DIN: 10639820) with effect from the closing hours of 14th August 2026. Details as required under Regulation30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as Annexure 2. Noted the Resignation of the Mr. Sanjay Jayantilal Jain, Independent Director (DIN: 03162189) with effect from the closing hours of 14th August 2026. Details as required under Regulation30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as Annexure 2. Corporate Office: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006 FISCHER MEDICAL VENTURES LIMITED (Formerly known as Fischer Chemic Limited) Registered Office Address: Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032 CIN: L86900AP1993PLC118162 Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548 3. Reconstitution of Audit Committee and Nomination and Remuneration Committee Pursuant to resignation of Independent Directors, the Board has approved the reconstitution of the Committees of the Board. Details as required under Regulation30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as Annexure 3. 4. Allotment of Equity shares pursuant to conversion of warrants The allotment of 2,05,05,909 (Two Crore Five Lakhs Five Thousand and Nine Hundred and Nine) Equity Shares of Re. 1/- (Rupee One only) each at an issue price of Rs. 23.4/- (Rupees Twenty Three and Forty Paise) per share, on preferential basis to the persons of promoters and non-promoter category, in accordance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the provisions of the Companies Act, 2013 and rules made there under as per the list enclosed and marked in Annexure 4. The Board Meeting commenced at 4:30 PM (IST) and concluded at 6:00 PM (IST) Please take on record. Thanking You, Yours Truly, For FISCHER MEDICAL VENTURES LIMITED BALAJI GANDLA COMPANY SECRETARY AND COMPLIANCE OFFICER Corporate Office: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006 Fischer Medical Ventures Limited CIN : L86900AP1993PLC118162 STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 (Amount in INR lakhs) Quarter ended Year ended Particulars June 30, 2026 June 30, 2025 March 31, 2026 March 31, 2026 (Unaudited) (Unaudited) (Audited) (Audited) Income I) Revenue From Operations 72.17 4 54.23 4 10.76 1,739.18 II) Other Income 89.06 80.40 43.40 349.34 III) Total Income (I+II) 1 61.23 5 34.63 4 54.16 2,088.52 Expenses : Purchase of Traded Goods 75.50 3 18.59 2 76.83 1,195.68 Changes in inventories of finished goods, by-products and work in progress (7.78) - 4.58 (35.45) Employee Benefit expenses 56.43 41.75 52.39 201.51 Finance Cost 1 47.32 1 30.88 1 26.55 465.23 Depreciation and Amortization Expenses 76.74 8.16 43.39 6 7.86 Other Expenses 1 36.00 56.81 9 67.10 1,244.27 IV) Total Expenses (IV) 4 84.22 5 56.19 1 ,470.84 3,139.11 V) Profit (Loss) Before exceptional item and tax (III-IV) (322.99) (21.56) (1,016.68) (1,050.58) VI) Exceptional Items - - - - VII) Profit before tax (V-VI) (322.99) (21.56) (1,016.68) (1,050.58) VIII) Tax Expenses i) Current Tax - - - - ii) Deferred Tax (27.42) (39.38) 1 27.50 1 7.29 iii) Tax pertaining to previous year - - (9.00) (9.00) IX) Profit (Loss) from Continuing Operations (VII-VIII) (350.41) (60.94) (898.18) (1,042.29) X) Other Comprehensive income; (i) Items that will not be reclassified to profit or loss - - - - (ii) Income tax relating to items that will not be reclassified to profit or los - - - - (iii) Items that will be reclassified to profit or loss - - - - (iv) Income tax relating to items that will be reclassified to profit or los - - - - Total Comprehensive Income for the period (Comprising profit/ (loss) and other Comprehensive Income for the period (IX-X) XI) (350.41) (60.94) (898.18) (1,042.29) Paid up Equity Share Capital (Face Value Re.1/-) XII) 6,545.15 6,485.15 6,545.15 6,545.15 XIII) Earnings per Equity Shares 1) Basic (0.05) (0.01) (0.14) (0.16) 2) Diluted (0.05) (0.01) (0.13) (0.15) Ravindran Govindan Chairman and Managing Director DIN: 03137661 NOTES: 1 The unaudited financial results of the Group for the quarter and year ended June 30, 2026 have been prepared in accordance with the Indian Accounting Standards ("Indian Accounting Standards ("Ind As") As Prescribed under section 133 of the Companies Act, 2013 as amended. 2 The unaudited financial results of the Group for the quarter ended June 30, 2026 have been reviewed by the audit committee on August 14, 2026 and thereafter Board of directors at their meeting held on August 14, 2026. 3 The Group is primarily engaged in one business segment in accordance with the requirement of Indian Accounting Standards (Ind As) 108: Operating Segment. Accordingly, no separate segment information has been provided. 4 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year. 5 Subsequent Event Subsequent to the reporting period, the Company’s Board of Directors, through Circular Resolutions dated August 11, August 12 and August 13 2026, approved the allotment of equity shares upon conversion of convertible warrants, pursuant to the exercise of the conversion option by the respective warrant holders. The details of the allotments are as follows: • 11 August 2026: The Board approved the allotment of 23,00,000 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹4,03,65,000. • 12 August 2026: The Board approved the allotment of 66,31,664 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a [Showing first 8,000 characters — download PDF for full document]